Repeated Cannabinoid Exposure Changed Retinal CB1 Signaling and Experimental Neuroprotection in Rats

A rat retinal study found that repeated cannabinoid exposure reduced CB1 expression and altered subsequent protection against an experimental excitotoxic injury. Lower-dose HU-210 conditions showed protection where other repeated-treatment conditions did not.

The tissue and injury model were specific

Researchers studied normal rat retina and an AMPA excitotoxicity model using anandamide, methanandamide and HU-210. Receptor expression, signaling-protein phosphorylation and selected amacrine-cell outcomes were measured. This was not a clinical trial of cannabis for vision preservation.

Expression and downstream responses differed by compound

Repeated exposure reduced CB1 expression under several conditions, while a lower tested dose did not. HU-210 and methanandamide affected selected Akt or ERK phosphorylation measures. Anandamide did not produce those same downstream changes. The abstract does not support treating all three compounds as identical signaling interventions.

Protection was not guaranteed by cannabinoid exposure

The three compounds failed to protect the selected amacrine cells under one repeated-treatment condition, whereas lower HU-210 doses were protective. This suggests a dose- and regimen-sensitive relationship. It does not establish that receptor downregulation alone caused loss of protection or that a consumer low dose would reproduce the result.

The study contributes evidence that repeated exposure may alter a cannabinoid's subsequent effect in retina. Its clinical implications remain limited by the animal model, selected cell population and laboratory injury. It cannot establish a treatment for retinal disease or a safe human dosing strategy.

Related: interpreting cannabis tolerance claims.

Research cited

Papadogkonaki S; Theodorakis Κ; Thermos K. Endogenous and synthetic cannabinoids induce the downregulation of cannabinoid CB1 receptor in retina. Experimental eye research (2019). doi:10.1016/j.exer.2019.107694. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Acute THC Altered Adrenal Catecholamine Stores Without a Matching Enzyme Decline

An experimental THC study found lower adrenal-medullary catecholamine stores after acute exposure without a statistically significant decline in a key synthesis enzyme. The changes disappeared with repeated treatment, while circulating hormones followed partly different patterns. Tissue content and enzyme activity were separate measures Acute THC decreased adrenal norepinephrine and epinephrine…

Spread the love

Read Article: Acute THC Altered Adrenal Catecholamine Stores Without a Matching Enzyme Decline

Rimonabant Analogues Produced Cannabinoid-Like Mouse Behaviors Without THC-Like Drug Cues

Some experimental rimonabant analogues produced cannabinoid-like effects in mouse tests but did not reproduce THC's learned drug cue. Other comparisons also separated the compounds from THC, cautioning against equating a similar outward profile with the same pharmacology. Behavioral similarity was only the starting point O-6629 and O-6658 produced dose-dependent effects…

Spread the love

Read Article: Rimonabant Analogues Produced Cannabinoid-Like Mouse Behaviors Without THC-Like Drug Cues

Whole-Brain Receptor Assays Stayed Unchanged Despite Marked THC Behavioral Tolerance in Mice

A mouse study detected substantial THC behavioral tolerance without significant changes in whole-brain receptor binding or mRNA. The result limits a simple whole-brain explanation while leaving regional or functional changes unresolved. Behavior and biochemical assays were different endpoints Mice received THC twice daily for six and a half days. Testing…

Spread the love

Read Article: Whole-Brain Receptor Assays Stayed Unchanged Despite Marked THC Behavioral Tolerance in Mice

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us